Zobrazeno 1 - 10
of 1 710
pro vyhledávání: '"kras mutations"'
Autor:
Mingzhen Bai, Ruoshui Wang, Chongfei Huang, Ruyang Zhong, Ningzu Jiang, Wenkang Fu, Ningning Mi, Long Gao, Yuyao Jin, Haidong Ma, Jie Cao, Haiying Yu, Qiang Jing, Chao Zhang, Ping Yue, Yong Zhang, Yanyan Lin, Hengwei Zhang, Wenbo Meng
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Distal cholangiocarcinoma is a rare and highly aggressive malignant tumor. The inherent tumor characteristics and growth pattern of cancer cells pose a challenge for diagnosis and treatment. Chemotherapy resistance leads to limited treatment
Externí odkaz:
https://doaj.org/article/d768550e8ec847dc99ac103f084fabbe
Autor:
Hanyu Shen, Chunxiao Li
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundImmunotherapy, frequently combined with conventional chemotherapy, is crucial for treating NSCLC. Kirsten rat sarcoma virus (KRAS) is a poor prognostic factor in patients with NSCLC, particularly lung adenocarcinoma, where binding of conven
Externí odkaz:
https://doaj.org/article/979951eeb244414d8c3aeb81e00b525c
Publikováno v:
Heliyon, Vol 10, Iss 9, Pp e28881- (2024)
Pulmonary mucinous adenocarcinoma (PMA), a distinct subtype of non-small cell lung cancer (NSCLC), is characterized by an abundance of mucin-producing cells. Although this subtype comprises a relatively small fraction of lung adenocarcinomas, PMA sta
Externí odkaz:
https://doaj.org/article/9a5af457e5a5402092979f6b9f6ddd86
Autor:
Lasse Bøllehuus Hansen, Sandra Fugl Jakobsen, Egija Zole, Julie Boertmann Noer, Li Tai Fang, Sefa Alizadeh, Julia Sidenius Johansen, Marghoob Mohiyuddin, Birgitte Regenberg
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17679-17691 (2023)
Abstract Backgrounds Despite recent advances, many cancers are still detected too late for curative treatment. There is, therefore, a need for the development of new diagnostic methods and biomarkers. One approach may arise from the detection of extr
Externí odkaz:
https://doaj.org/article/ca8394e32a374f9c84d0a8c522769fba
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionPancreatic ductal adenocarcinoma (PDAC) has the highest mortality rate among all solid tumors. Tumorigenesis is promoted by the oncogene KRAS, and KRAS mutations are prevalent in patients with PDAC. Therefore, a comprehensive understandin
Externí odkaz:
https://doaj.org/article/5475e92c088d4a838e63acf1ef2dfb2d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Anna K. Rekowska, Piotr Rola, Agnieszka Kwiatkowska, Magdalena Wójcik-Superczyńska, Michał Gil, Paweł Krawczyk, Janusz Milanowski
Publikováno v:
Biomedicines, Vol 12, Iss 2, p 325 (2024)
Mutations in the KRAS gene are among the most common mutations observed in cancer cells, but they have only recently become an achievable goal for targeted therapies. Two KRAS inhibitors, sotorasib and adagrasib, have recently been approved for the t
Externí odkaz:
https://doaj.org/article/05ffdb3edf2a4b11b59be44081022dac
Autor:
Mark Jain, David Atayan, Tagir Rakhmatullin, Tatyana Dakhtler, Pavel Popov, Pavel Kim, Mikhail Viborniy, Iuliia Gontareva, Larisa Samokhodskaya, Vyacheslav Egorov
Publikováno v:
Biomedicines, Vol 12, Iss 1, p 220 (2024)
The key challenge of cell-free tumor DNA (cftDNA) analysis in pancreatic ductal adenocarcinoma (PDAC) is overcoming its low detection rate, which is mainly explained by the overall scarcity of this biomarker in plasma. Obstructive jaundice is a frequ
Externí odkaz:
https://doaj.org/article/b9d27399d436404b81cf3d9204ba2ba2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.